These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1227 related items for PubMed ID: 19334039

  • 1. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y, Harada H.
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [Abstract] [Full Text] [Related]

  • 2. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y, Harada H.
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [Abstract] [Full Text] [Related]

  • 3. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H, Harada H, Harada Y, Ding Y, Imagawa J, Inaba T, Kyo T, Kimura A.
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [Abstract] [Full Text] [Related]

  • 4. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
    Harada H.
    Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
    [No Abstract] [Full Text] [Related]

  • 5. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
    Nakao M, Horiike S, Fukushima-Nakase Y, Nishimura M, Fujita Y, Taniwaki M, Okuda T.
    Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
    [Abstract] [Full Text] [Related]

  • 6. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A, Savva N, Mishkova O, Aleinikova OV.
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [Abstract] [Full Text] [Related]

  • 7. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
    Taketani T, Taki T, Takita J, Tsuchida M, Hanada R, Hongo T, Kaneko T, Manabe A, Ida K, Hayashi Y.
    Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
    [Abstract] [Full Text] [Related]

  • 8. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H, Harada Y.
    Crit Rev Eukaryot Gene Expr; 2005 Sep; 15(3):183-96. PubMed ID: 16390315
    [Abstract] [Full Text] [Related]

  • 9. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
    Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR.
    Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
    [Abstract] [Full Text] [Related]

  • 10. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
    Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T, Kitamura T.
    Blood; 2008 Apr 15; 111(8):4297-308. PubMed ID: 18192504
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Molecular bases of myelodysplastic syndromes: lessons from animal models.
    Komeno Y, Kitaura J, Kitamura T.
    J Cell Physiol; 2009 Jun 15; 219(3):529-34. PubMed ID: 19259975
    [Abstract] [Full Text] [Related]

  • 13. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
    Harada H, Harada Y, Kimura A.
    Curr Cancer Drug Targets; 2006 Sep 15; 6(6):553-65. PubMed ID: 17017876
    [Abstract] [Full Text] [Related]

  • 14. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.
    Exp Hematol; 2007 Apr 15; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [Abstract] [Full Text] [Related]

  • 15. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
    Osato M.
    Oncogene; 2004 May 24; 23(24):4284-96. PubMed ID: 15156185
    [Abstract] [Full Text] [Related]

  • 16. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.
    Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, Matsui K, Shibata M, Mizuki M, Kanakura Y.
    Leukemia; 2012 Feb 24; 26(2):303-11. PubMed ID: 21836608
    [Abstract] [Full Text] [Related]

  • 17. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P.
    Br J Haematol; 2008 Sep 24; 142(5):695-708. PubMed ID: 18540941
    [Abstract] [Full Text] [Related]

  • 18. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
    Cammenga J, Niebuhr B, Horn S, Bergholz U, Putz G, Buchholz F, Löhler J, Stocking C.
    Cancer Res; 2007 Jan 15; 67(2):537-45. PubMed ID: 17234761
    [Abstract] [Full Text] [Related]

  • 19. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
    Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.
    Cancer Res; 2011 Apr 01; 71(7):2761-71. PubMed ID: 21447743
    [Abstract] [Full Text] [Related]

  • 20. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation.
    Shen S, Passioura T, Symonds G, Dolnikov A.
    Exp Hematol; 2007 Jun 01; 35(6):908-19. PubMed ID: 17533045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.